Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.

Original title: “AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win”

Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other anti-amyloid Alzheimer’s disease therapy on the market.

Original title: “Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi”

Breakwater data show significant survival gains over standard chemotherapy

Original title: “EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC”

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.

Original title: “Q32 bounces back to claim study success for alopecia drug”

Non-hormonal option to be made available for patients unsuitable for HRT

Original title: “SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms”

Forward-Looking Statements This ... in the treatment of Alzheimer’s disease; Voyager’s advancement of the VY1706 program, including the timing and achievement of clinical development milestones such as Voyager’s intentions to initiate clinical trials, clinical trial enrollment, and dosing of adults with early Alzheimer’s disease in the second half of 2026; the therapeutic potential, ... Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, implied and express statements about Voyager’s beliefs and expectations regarding the potential of tau as a transformational target in the treatment of Alzheimer’s disease; Voyager’s advancement of the VY1706 program, including the timing and achievement of clinical development milestones such as Voyager’s intentions to initiate clinical trials, clinical trial enrollment, and dosing of adults with early Alzheimer’s disease in the second half of 2026; the therapeutic potential, safety, and pharmacological effect of VY1706; Voyager’s ability to execute across its pipeline and platforms; and the mission and goals for Voyager’s business. - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq:... Voyager is initiating a clinical trial of VY1706 administered as a one-time IV dose to adults with early AD. About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. In June, Voyager received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for VY1706, enabling initiation of a clinical trial in adults with early AD, with dosing expected to begin in the second half of the year. In May, the Company presented three-month GLP toxicology data for VY1706 at the American Society of Gene & Cell Therapy’s (ASGCT) 2026 Annual Meeting.

Original title: “Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026”

PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata   Desogestrel- and etonogestrel-…, Agenda Agenda of the PRAC meeting 6-9 July 2026Draft Reference Number: EMA/PRAC/141965/2026…, PRAC statistics: July 2026 , PRAC statistics: July 2026 English (EN) (174.12 KB - PDF)First published: 10/07/2026 View

Original title: “Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2026”

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

Original title: “Roche scraps two Ionis-partnered Huntington’s drugs”

The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.

Original title: “AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3”

New option for adults with IPF and PPF

Original title: “Jascayd gains UK licence for treatment of pulmonary fibrosis”

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

Original title: “Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy”

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

Original title: “Compass Pathways reports six‑month data confirming durable profile of COMP360”